Biogen (BIIB) Tops Q3 EPS by 62c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Biogen (BIIB) PT Raised to $364 at RBC Capital
October 24, 2018 6:55 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Biogen (NASDAQ: BIIB) to $364.00 (from $344.00) while maintaining a Sector Perform rating following results.
The analsyt notes Solid Commercial Execution, R&D Progress To Diversify Around Adu Binary.
... More